ME01029B - VIŠESUPTITUISANI DERIVATI 2-ARIL-6-FENIL-IMIDAZO [1, 2α] PIRIDINI, NJIHOVO DOBIJANJE I NJIHOVA UPOTREBA U TERAPIJI - Google Patents

VIŠESUPTITUISANI DERIVATI 2-ARIL-6-FENIL-IMIDAZO [1, 2α] PIRIDINI, NJIHOVO DOBIJANJE I NJIHOVA UPOTREBA U TERAPIJI

Info

Publication number
ME01029B
ME01029B MEP-2010-155A MEP15510A ME01029B ME 01029 B ME01029 B ME 01029B ME P15510 A MEP15510 A ME P15510A ME 01029 B ME01029 B ME 01029B
Authority
ME
Montenegro
Prior art keywords
alkyl
phenyl
pyridin
group
alkoxy
Prior art date
Application number
MEP-2010-155A
Other languages
English (en)
French (fr)
Inventor
Garcia Antonio Almario
Peretti Danielle De
Yannick Evanno
André Malanda
Patrick Lardenois
Nathalie Rakotoarisoa
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39764952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01029(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ME01029B publication Critical patent/ME01029B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Jedinjenja formule (I):   u kojoj: R 1  predstavlja: heteroaril ili heterocikličnu grupu, koje obe po izboru mogu da budu supstituisane, X predstavlja od 1 do 4 supstituenata, koji su identični ili različiti jedan od drugog, izabrani od vodonika, halogena, (C 1 -C 10 )alkil, halo(C 1 -C 10 )alkoksi, (C 1 -C 10 )alkoksi, NRaRb, cijano ili nitro, R predstavlja, na položaju 3, 5, 7 or 8 imidazo[l, 2-α]piridina, od 1 do 4 substituenta, koji su identični ili različiti jedan od drugog; R 2  i R 3  predstavljaju, nezavisno jedan od drugog, atom vodonika, ili po izboru supstituisanu (C 1 -C 10 )alkil grupu, ili po izboru supstituisanu aril grupu; R 2  i X mogu da formiraju, zajedno sa atomom ugljenika za koji vezani, ugjlenični prsten sa 5 do 7 atoma ugljenika; i R 4  predstavlja: atom vodonika; po izboru supstituisanu (C 1 -C 10 )alkil grupu; ili aril grupu po izboru supstituisanu jednim ili više suostituenata. Terapeutska upotreba ovih jedinjenja i procesi za njihovu sintezu.

Claims (10)

1. Jedinjenja formule (I): R1 predstavlja: fenil grupu ili naftil grupu, moguće je za ove dve grupe da su po izboru supstituisane jednim ili više atoma ili grupa odabranih, jezavisno jedno od drugog, od sledećih atoma ili grupa: halogen, (C1-C10)alkil, halo(C1-C10)alkil, (C1-C10)alkoksi, halo(C1-C10)alkoksi, (C1-C10)tioalkil, -S(0)(C1-C10)alkil, -S(0)2(C1-C10)alkil, hidroksil, cijano, nitro, hidroksi (C1-C10)alkilen, NRaRb(C1-C10)alkilen, (C1-C10)alkoksi(C1-C10)alkilen- oksi, NRaRb, CONRaRb, S02NRaRb, NRcCORd. 0C(0)NRaRb, OCO(C1-C10)alkil, NRcC(O)ORe, NRcS02Re, aril(C1-C10)alkilen, monociklični aril ili monociklični heteroaril, monociklični aril ili monociklični heteroaril po izboru je supstituisan jednim ili više supstituenata odabranih od halogena ili (C1-C10)alkil, halo(C1-C10)alkila (C1-C10)alkoksi, halo(C1-C10)alkoksi, NRaRb, hidroksil, okso, nitro, cijano ili OCO(C1-C10)alkil grupe; X predstavlja od 1 do 4 supstituenta koji su isti ili se međusobno razliku i koji su odabrani od vodonika, halogena, (C1-C10)alkila, (C1-C10)alkoksi, NRaRb, cijano, nitro, moguće je za (C1-C10)alkil da bude po izboru supstituisan jednom ili više grupa odabranih od halogena, (C1-C10)alkoksi, halo(C1-C10)alkoksi, NRaRb ili hidroksila; R predstavlja na položajim 3, 5, 7 ili 8 u Pimidazo [1, 2 α] piridinu od 1 do 4 ista ili različita supstituenta odabrana od halogena, (C1-C10) alkil, halo (C1-C10) alkil, (C1-C10) alkoksi; R2 i R3 predstavljaju, nezavisno jedan od drugog, atom vodonika, (C1-C10)alkil grupu, ova grupa je po izboru supstituisana sa Rf grupom; aril grupu, po izboru supstituisanu jednim ili više supstituenata odabranih od halogena ili (C1-C10)alkil, halo(C1-C10)alkil, (C1-C10)alkoksi, halo(C1-C10)alkoksi, NRaRb, hidroksil. nitro ili cijano grupe; R2 i X mogu zajedno da formiraju, sa atomima ugljenika koji ih nose, ugljenični prsten od 5 do 7 atoma ugljenika; R4 predstavlja: atom vodonika, (C1-C10)alkil grupu, ova grupa je po izboru supstituisana sa Rf grupom; aril grupu, po izboru supstituisanu jednim ili više supstituenata odabranih od halogena, (C1-C10)alkil, halo(C1-C10)alkil, (C1-C10)aIkoksi, halo(C1-C10)alkoksi, NRaRb, hidroksil, nitro, cijano, (C1-C10)alkil(CO)-, CONRaRb, NRcCORd, OC(0)NRaRb, OCO(C1-C10)alkil, NRcC(O)ORe ili aril grupe, aril je po izboru supstituted jednim ili više supstituenata odabranih od halogena, (C1-C10)alkil, halo(C1-C10)alkil, (C1-C10)alkoksi, halo(C1-C10)alkoksi, NRaRb, hidroksil, nitro ili cijano grupe; Ra i Rb predstavljaju, nezavisno jedan od drugog, atom vodonika ili (C1-C10)alkil, aril(C1-C10)alkilen ili aril grupu; ili Ra i Rb zajedno formiraju (C2-C5)alkilen grupu; Re predstavlja (C1-C10)alkil, aril(C1-C10)alkilen, aril grupu; ili Rc i Rd zajedno formiraju (C2-C5)alkilen grupu; Rf predstavlja atom halogena ili (C1-C10)alkoksi, halo(C1-C10)alkoksi, hidroksil, cijano, NRaRb, C(0)NRaRb, NRcCORd, OC(O)NRaRb, OCO(C1-C10)alkil, NRcCOORe, S02NRaRb, NRcS02Re, aril(C1-C10)alkilen ili aril grupu, aril je po izboru supstituisan jednim ili više supstituenata odabranih od halogena ili (C1-C10)alkil, halo(C1-C10)alkil, (C1-C10)alkoksi, halo(C1-C10)alkoksi, NRaRb, hidroksil, nitro, cijano ili OCO(C1-C10)alkil grupe; u obliku baze ili adicione soli sa kiselinom.
2.    Jedinjenja formule (I) prema zahtevu 1, naznačena time, što: R1 predstavlja fenil grupu ili naftil grupu po izboru supstituisanu jednim ili više atoma ili grupa odabranih, nezavisno jedan od drugog, od atoma halogena ili (C1-C10)alkil, (C1-C10)alkoksim halo(C1-C10)aIkoksi,
3.    Jedinjenja formule (I) prema zahtevu 1 ili 2, naznačena time, što: X predstavlja 1 ili 2 supstituenta, ista ili koji se razlikuju jedan od drugog, odabrana od atoma vodonika; halogena;
4. Jedinjenja formule (I) prema jednom od prethodnih zahteva, naznačena time, što: R predstavlja, u položaju 3, 7 ili 8 u imidazo [1, 2 α] piridinu, 1 ili 2 supstituenta, ista ili međusobno različita, odabrana od atoma halogena, (C1-C10)alkil grupe;
5.    Jedinjenja formule (I) prema jednom od prethodnih zahteva, naznačena time, što: R2 i R3 predstavljaju, nezavisno jedan od drugog, atom vodonika ili (C1-C10)alkil grupu;
6.    Jedinjenja formule (I) prema jednom od prethodnih zahteva, naznačena time, što: R4 predstavlja, atom vodonika ili (C1-C10)alkil grupu;
7. Jedinjenja formule (I) prema jednom od prethodnih zahteva, naznačena time, što: grupa je na fenil prstenu u položaju 2, 3 ili 4;
8. Jedinjenja formule (I) prema jednom od prethodnih zahteva, naznačena time, što: R1 predstavlja fenil grupu ili naftil grupu, po izboru supstituisanu jednim ili više atoma ili grupa odabranih, nezavisno jedan od drugog, od atoma halogena, ili (C1-C10)alkil ili (C1-C10)alkoksi, halo (C1-C10)alkoksi grupu; X predstavlja 1 ili 2 supstituenta, ista ili koji se razlikuju jedan od drugog, odabrana od atoma vodonika ili atoma halogena; R predstavlja u položaju 3, 7 ili 8 u imidazo [1, 2 α] piridinu, 1 ili 2 supstituenta, ista ili međusobno različita, odabrana od atoma halogena, (C1-C10)alkil grupe; R2 i R3 predstavljaju, nezavisno jedan od drugog, atom vodonika ili (C1-C10)alkil grupu; R4 predstavlja atom vodonika ili (C1-C10)alkil grupu; grupa je na fenil prstenu u položaju 2, 3 ili 4;
9. Jedinjenja formule (I) prema jednom od prethodnih zahteva, naznačena time, što R1 predstavlja fenil grupu ili naftil grupu, ove dve grupe su po izboru supstituisane jednim ili više atoma ili sledećih grupa odabranih, nezavisno jedna od druge, od halogena, (C1-C10)alkil ili (C1-C10)alkoksi, halo (C1-C10)alkoksi grupe; X predstavlja atoma vodonika; R je u položaju 3, 7 ili 8 u imidazo [1, 2 α] piridinu, 1 ili 2 supstituenta, i predstavlja, (C1-C10)alkil; R2 i R3 predstavljaju, nezavisno jedan od drugog, atom vodonika; R4 predstavlja atom vodonika u obliku baze ili adicione soli sa kiselinom.
10. Jedinjenja: {3 [2 (4-Hlorfenil) - 8-metilimidazo [1, 2 -α] piridin-6-il] fenil} metanol; {3 [2 (4-Hlorfenil) - 7-metilimidazo [1, 2 -α] piridin-6-il] fenil} metanol; [3 (3-Metil-2-fenilimidazo [1, 2 -α] piridin-6-il) fenil] metanol; {3 [2 (2, 4-difluorofenil) - 3-metilimidazo [1, 2 -α] piridin-6-il] fenil} metanol i njegov hidrohlorid; {3 [2 (4-hlor-3-meti! fenil) - 3-metilimidazo [1, 2 -α] piridin-6 ii] fenil} metanol i njegov hidrohlorid; {3 [2 (4-hlorfenil) - 3-metilimidazo [1, 2- α] piridin-6-il] fenil} metanol i njegov hidrohlorid; {3 [2 (4-metoksifenil) - 3-metilimidazo [1, 2 -α] piridin-6-il] fenil} metanol i njegov hidrohlorid; {3 [2 [4 (difluorometiloksi) fenil] - 3-metilimidazo [1, 2 -α] piridin-6 ii] fenil} metanol i njegov hidrohlorid; [3 (8-Metil-2-naftil-2-ilimidazo [1, 2 -α] piridin-6-il) fenil] metanol; [4 (8-Metil-2-naftil-2-ilimidazo [1, 2 - α] piridin-6-il) fenil] metanol; 2 [3 (3-Metil-2-fenilimidazo [1. 2 -α] piridin-6-il) fenil] propan-2-ol; 2 {3 [2 (4-Hlorfenil) - 3-metilimidazo [1, 2 -α] piridin-6-il] fenil} propan-2-ol; 2 {3 [2 (3-Hlorfenil) - 3-metilimidazo [1, 2 -α] piridin-6-il] fenil} propan-2-ol; 2 {3 [2 (2, 4-Difluorofenil) - 3-metilimidazo [1, 2 -α]] piridin-6-il] fenil} propan-2- ol; 2- {3 - [2 (4-Metoksifenil) - 3 - methy limidazo [1, 2 -α] piridin-6-il] fenil} propan-2- ol; {2-Fluoro-6- [2 (4-metoksifenil) - 3-metilimidazo [1, 2-α] piridin-6 ii] fenil} metanol; [2, 6-Difluoro-3- (3-metil-2-fenilimidazo [1, 2 -α ] piridin-6-il) fenil] metanol; {3 [2 (4-Hlorfenil) - 3-metilimidazo [1, 2 -α] piridin-6-il] - 2, 6 - difluorofenil} metanol; {3 [2 (3-Hlorfenil) - 3-metilimidazo [1, 2 -α ] piridin-6-il] - 2, 6 - difluorofenil} metanol; {2, 6-Difluoro-3- [2 (4-metoksifenil) - 3-metilimidazo [1, 2 -α ] piridin-6-il] - fenil} - metanol; {3 - [3 - Hlor-2 (4-hlorfenil) imidazo [1, 2 -α] piridin-6-il] fenil} metanol; 2 {3 [2 (4-Hlorfenil) - 3-fluoroimidazo [1, 2 -α ] piridin-6-il] fenil} propan-2-ol; 2 {3 [3-Hlor-2 (4-hlorfenil) imidazo [1, 2 -α ] piridin-6-il] fenil} propan-2-ol; [2-Fluoro-6- (3-metil-2-fenilimidazo [1, 2 -α ] piridin-6-il) fenil] metanol; {2 [2 (4-Hlorfenil) - 3-metilimidazo [1, 2 -α] piridin-6-il] - 6 - fluorofenil} metanol; {2 [2 (3-Hlorfenil) - 3-metilimidazo [1, 2 -α ] piridin-6-il] - 6 - fluorofenil} metanol;
MEP-2010-155A 2008-03-21 2009-03-20 VIŠESUPTITUISANI DERIVATI 2-ARIL-6-FENIL-IMIDAZO [1, 2α] PIRIDINI, NJIHOVO DOBIJANJE I NJIHOVA UPOTREBA U TERAPIJI ME01029B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0801581A FR2928922B1 (fr) 2008-03-21 2008-03-21 Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
PCT/FR2009/000302 WO2009144394A1 (fr) 2008-03-21 2009-03-20 Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines polysubstitues, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
ME01029B true ME01029B (me) 2012-10-20

Family

ID=39764952

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2010-155A ME01029B (me) 2008-03-21 2009-03-20 VIŠESUPTITUISANI DERIVATI 2-ARIL-6-FENIL-IMIDAZO [1, 2α] PIRIDINI, NJIHOVO DOBIJANJE I NJIHOVA UPOTREBA U TERAPIJI

Country Status (23)

Country Link
US (1) US8507520B2 (me)
EP (1) EP2262769B1 (me)
JP (1) JP5508385B2 (me)
KR (1) KR20100129775A (me)
CN (2) CN103193815A (me)
AR (1) AR070993A1 (me)
AU (1) AU2009253234B2 (me)
BR (1) BRPI0909415A2 (me)
CA (1) CA2719125C (me)
CL (1) CL2009000696A1 (me)
CO (1) CO6290657A2 (me)
EA (1) EA201071112A1 (me)
FR (1) FR2928922B1 (me)
IL (1) IL208246A0 (me)
MA (1) MA32247B1 (me)
ME (1) ME01029B (me)
MX (1) MX2010010316A (me)
NZ (1) NZ588151A (me)
SG (1) SG189679A1 (me)
TW (1) TW200944202A (me)
UY (1) UY31728A (me)
WO (1) WO2009144394A1 (me)
ZA (1) ZA201006728B (me)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426441B2 (en) * 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2950345B1 (fr) * 2009-09-18 2011-09-23 Sanofi Aventis Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
US9295384B2 (en) * 2014-05-16 2016-03-29 Novartis Ag Imaging probes and associated devices, systems, and methods utilizing lever arm actuators
RU2729187C1 (ru) * 2015-09-29 2020-08-05 Онкотерапи Сайенс, Инк. Бициклическое соединение и его применение для ингибирования suv39h2
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US20240294529A1 (en) * 2021-07-16 2024-09-05 Sanofi 6h-imidazo[1,2-a]pyrrolo[2,3-e]pyridine derivatives for use in therapy
JP2024525791A (ja) * 2021-07-16 2024-07-12 サノフイ 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039782D1 (de) * 1999-12-06 2008-09-18 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
CA2517256C (en) 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903106B1 (fr) * 2006-07-03 2010-07-30 Sanofi Aventis Utilisations de 2-benzoyl-imidazopyridines en therapeutique
FR2903105A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques

Also Published As

Publication number Publication date
EP2262769B1 (fr) 2014-11-05
US20110065745A1 (en) 2011-03-17
EP2262769A1 (fr) 2010-12-22
IL208246A0 (en) 2010-12-30
FR2928922B1 (fr) 2010-04-23
FR2928922A1 (fr) 2009-09-25
SG189679A1 (en) 2013-05-31
CO6290657A2 (es) 2011-06-20
CA2719125A1 (fr) 2009-12-03
KR20100129775A (ko) 2010-12-09
ZA201006728B (en) 2011-11-30
JP2011515382A (ja) 2011-05-19
AR070993A1 (es) 2010-05-19
CA2719125C (fr) 2016-07-26
JP5508385B2 (ja) 2014-05-28
TW200944202A (en) 2009-11-01
US8507520B2 (en) 2013-08-13
CN102036959A (zh) 2011-04-27
MX2010010316A (es) 2010-12-14
CN103193815A (zh) 2013-07-10
BRPI0909415A2 (pt) 2019-01-15
AU2009253234A1 (en) 2009-12-03
WO2009144394A1 (fr) 2009-12-03
AU2009253234B2 (en) 2013-07-11
NZ588151A (en) 2012-07-27
UY31728A (es) 2009-11-10
CN102036959B (zh) 2013-05-22
CL2009000696A1 (es) 2010-08-13
MA32247B1 (fr) 2011-04-01
EA201071112A1 (ru) 2011-04-29
WO2009144394A8 (fr) 2010-10-14

Similar Documents

Publication Publication Date Title
ME01029B (me) VIŠESUPTITUISANI DERIVATI 2-ARIL-6-FENIL-IMIDAZO [1, 2α] PIRIDINI, NJIHOVO DOBIJANJE I NJIHOVA UPOTREBA U TERAPIJI
TW200942541A (en) Polysubstituted 6-heteroarylimidazo[1,2-α]pyridine derivatives, preparation thereof and therapeutic use thereof
EA201071113A1 (ru) ПОЛИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ГЕТЕРОАРИЛ-6-ФЕНИЛИМИДАЗО[1,2-α] ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
EA201071110A1 (ru) ПОЛИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
MEP10709A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-alpha]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MY156456A (en) Morpholinopurine derivatives
TN2017000044A1 (en) Aminopyrimidinyl compounds as jak inhibitors
EP1719763A4 (en) NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2)
AR070521A1 (es) Derivados de 4h-pirido[4,3-d]-pirimidin-4-ona,inhibidores de quinasas,composiciones farmaceuticas que los contienen,uso de los mismos para el tratamiento de enfermedades con proliferacion celular o autoinmunes y metodo de preparacion de intermediarios de sintesis .
PH12014501486A1 (en) Novel nicotinamide derivative or salt thereof
CA2489824A1 (en) Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
RU2012136624A (ru) Фармацевтические композиции для лечения боли и других показаний
AR067008A1 (es) Derivados 3- amino-6-(1- amino - etil)-tetrahidropirano
ES2409404T3 (es) Compuestos heterocíclicos de fenoximetilo
JP2011520775A5 (me)
EP3643715A1 (en) Nitrogen heteroaryl derivative having csf1r inhibitory activity, and preparation method therefor and application thereof
EA200901375A1 (ru) Производные пиридазина, пиридина и пирана в качестве агонистов рецептора gpbar1
RU2015145479A (ru) Производные пиразолонафтиридинона в качестве ингибиторов метар2(метионинаминопептидазы 2 типа)
RU2013128602A (ru) Производные дифениламина: применение, способ синтеза и фрамацевтические композиции
JP2014505662A5 (me)
RU2010123003A (ru) Способы получения и промежуточные соединения для получения аминобензимидазолмочевин
MX2009008492A (es) Derivados de azabicicloalcano, su preparacion y su aplicación en terapeutica.
JP2021500344A (ja) 農薬としてのベンゾイミダゾール化合物
TW200942539A (en) N-phenylimidazo[1,2-α]pyridine-2-carboxamide derivatives, their preparation and their therapeutic application
MX2008001034A (es) Nuevos derivados de pirido[3',2':4,5]furo[3,2-d]pirimidina.